Skip to main content
Livermore
Livermore
ZHEN

CAPROCK Group, Inc.

SEC CIK
0001610769
Latest filing
Jul 27, 2026

TAK holding history

Takeda Pharmaceutical Co Ltd in every 13F filed by CAPROCK Group, Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

TAK overviewAll 13F holders of TAKFull Q2 2026 holdings

Shares (Q2 2026)
40,725
Value
$666.1K
% of portfolio
<0.1%
Quarters held
18
Since Q1 2021
Holdings of TAK by CAPROCK Group, Inc., by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 202640,725$666.1K<0.1%−2,416−5.6%ReducedHolders
Q1 202643,141$799.0K<0.1%+6,869+18.9%AddedHolders
Q4 202536,272$565.5K<0.1%−17,189−32.2%ReducedHolders
Q3 202553,461$801.4K<0.1%–No prior filingHolders
Q2 2025––––Not filedHolders
Q1 202528,398$422.3K<0.1%+2,485+9.6%AddedHolders
Q4 202425,913$343.1K<0.1%−8,391−24.5%ReducedHolders
Q3 202434,304$487.8K<0.1%+2,454+7.7%AddedHolders
Q2 202431,850$422.8K<0.1%+2,830+9.8%AddedHolders
Q1 202429,020$403.1K<0.1%−3,887−11.8%ReducedHolders
Q4 202332,907$469.6K<0.1%−34,369−51.1%ReducedHolders
Q3 202367,276$1.04M0.1%+9,906+17.3%AddedHolders
Q2 202357,370$915.0K0.1%+13,620+31.1%AddedHolders
Q1 202343,750$721.0K0.1%+9,609+28.1%AddedHolders
Q4 202234,141$532.6K<0.1%+34,141NewHolders
Q2 20220$00.0%−18,453−100.0%Sold outHolders
Q1 202218,453$264.0K<0.1%+3,216+21.1%AddedHolders
Q4 202115,237$208.0K<0.1%+3,397+28.7%AddedHolders
Q3 202111,840$194.0K<0.1%+11,840NewHolders
Q2 20210$00.0%−16,656−100.0%Sold outHolders
Q1 202116,656$304.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.